384 related articles for article (PubMed ID: 36395954)
41. Targeting cuproplasia and cuproptosis in cancer.
Tang D; Kroemer G; Kang R
Nat Rev Clin Oncol; 2024 May; 21(5):370-388. PubMed ID: 38486054
[TBL] [Abstract][Full Text] [Related]
42. Lactylation of METTL16 promotes cuproptosis via m
Sun L; Zhang Y; Yang B; Sun S; Zhang P; Luo Z; Feng T; Cui Z; Zhu T; Li Y; Qiu Z; Fan G; Huang C
Nat Commun; 2023 Oct; 14(1):6523. PubMed ID: 37863889
[TBL] [Abstract][Full Text] [Related]
43. Copper homeostasis and cuproptosis in tumor pathogenesis and therapeutic strategies.
Bian C; Zheng Z; Su J; Chang S; Yu H; Bao J; Xin Y; Jiang X
Front Pharmacol; 2023; 14():1271613. PubMed ID: 37767404
[TBL] [Abstract][Full Text] [Related]
44. The mechanism of copper transporters in ovarian cancer cells and the prospect of cuproptosis.
Guo J; Sun Y; Liu G
J Inorg Biochem; 2023 Oct; 247():112324. PubMed ID: 37481825
[TBL] [Abstract][Full Text] [Related]
45. Biomimetic gold nanocages incorporating copper-human serum albumin for tumor immunotherapy via cuproptosis-lactate regulation.
Zafar H; Zhang J; Raza F; Pan X; Hu Z; Feng H; Shen Q
J Control Release; 2024 Jun; 372():446-466. PubMed ID: 38917953
[TBL] [Abstract][Full Text] [Related]
46. Novel insights into anticancer mechanisms of elesclomol: More than a prooxidant drug.
Gao J; Wu X; Huang S; Zhao Z; He W; Song M
Redox Biol; 2023 Nov; 67():102891. PubMed ID: 37734229
[TBL] [Abstract][Full Text] [Related]
47. CuO Nanozymes Catalyze Cysteine and Glutathione Depletion Induced Ferroptosis and Cuproptosis for Synergistic Tumor Therapy.
Bai J; Zhang X; Zhao Z; Sun S; Cheng W; Yu H; Chang X; Wang B
Small; 2024 May; ():e2400326. PubMed ID: 38813723
[TBL] [Abstract][Full Text] [Related]
48. Cuproptosis identifies respiratory subtype of renal cancer that confers favorable prognosis.
Li K; Tan L; Li Y; Lyu Y; Zheng X; Jiang H; Zhang X; Wen H; Feng C
Apoptosis; 2022 Dec; 27(11-12):1004-1014. PubMed ID: 36103026
[TBL] [Abstract][Full Text] [Related]
49. Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer.
Jin L; Mei W; Liu X; Sun X; Xin S; Zhou Z; Zhang J; Zhang B; Chen P; Cai M; Ye L
Front Immunol; 2022; 13():974034. PubMed ID: 36203594
[TBL] [Abstract][Full Text] [Related]
50. Designing salicylaldehyde isonicotinoyl hydrazones as Cu(II) ionophores with tunable chelation and release of copper for hitting redox Achilles heel of cancer cells.
Ji Y; Dai F; Zhou B
Free Radic Biol Med; 2018 Dec; 129():215-226. PubMed ID: 30240704
[TBL] [Abstract][Full Text] [Related]
51. Copper homeostasis and cuproptosis in mitochondria.
Tian Z; Jiang S; Zhou J; Zhang W
Life Sci; 2023 Dec; 334():122223. PubMed ID: 38084674
[TBL] [Abstract][Full Text] [Related]
52. Cope with copper: From copper linked mechanisms to copper-based clinical cancer therapies.
Wang X; Zhou M; Liu Y; Si Z
Cancer Lett; 2023 May; 561():216157. PubMed ID: 37011869
[TBL] [Abstract][Full Text] [Related]
53. Copper in colorectal cancer: From copper-related mechanisms to clinical cancer therapies.
Wang Y; Pei P; Yang K; Guo L; Li Y
Clin Transl Med; 2024 Jun; 14(6):e1724. PubMed ID: 38804588
[TBL] [Abstract][Full Text] [Related]
54. Pan-cancer analysis of cuproptosis regulation patterns and identification of mTOR-target responder in clear cell renal cell carcinoma.
Long S; Wang Y; Chen Y; Fang T; Yao Y; Fu K
Biol Direct; 2022 Oct; 17(1):28. PubMed ID: 36209249
[TBL] [Abstract][Full Text] [Related]
55. Multifunctional nanomaterials
Ye L; Yu C; Xia J; Ni K; Zhang Y; Ying X; Xie D; Jin Y; Sun R; Tang R; Fan S; Yao S
Mater Today Bio; 2024 Apr; 25():100996. PubMed ID: 38420143
[TBL] [Abstract][Full Text] [Related]
56. 4-Octyl itaconate inhibits aerobic glycolysis by targeting GAPDH to promote cuproptosis in colorectal cancer.
Yang W; Wang Y; Huang Y; Yu J; Wang T; Li C; Yang L; Zhang P; Shi L; Yin Y; Tao K; Li R
Biomed Pharmacother; 2023 Mar; 159():114301. PubMed ID: 36706634
[TBL] [Abstract][Full Text] [Related]
57. Cuproptosis in cancer: biological implications and therapeutic opportunities.
Li L; Zhou H; Zhang C
Cell Mol Biol Lett; 2024 Jun; 29(1):91. PubMed ID: 38918694
[TBL] [Abstract][Full Text] [Related]
58. A novel cuproptosis-related molecular pattern and its tumor microenvironment characterization in colorectal cancer.
Zhu Z; Zhao Q; Song W; Weng J; Li S; Guo T; Zhu C; Xu Y
Front Immunol; 2022; 13():940774. PubMed ID: 36248908
[TBL] [Abstract][Full Text] [Related]
59. Exploring cuproptosis as a mechanism and potential intervention target in cardiovascular diseases.
Yang Y; Feng Q; Luan Y; Liu H; Jiao Y; Hao H; Yu B; Luan Y; Ren K
Front Pharmacol; 2023; 14():1229297. PubMed ID: 37637426
[TBL] [Abstract][Full Text] [Related]
60. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer.
Song S; Zhang M; Xie P; Wang S; Wang Y
Front Immunol; 2022; 13():978909. PubMed ID: 36341328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
